A Feasibility Study of the Nativis Voyager(TM) System in Patients with Recurrent Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with first or second recurrence of GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus lomustine (CCNU). Safety and clinical utility will be evaluated.

Participate in a Clinical Trial

Learn More